Investors Purchase High Volume of Put Options on Revolution Medicines (NASDAQ:RVMD)

Revolution Medicines, Inc. (NASDAQ:RVMD) was the recipient of some unusual options trading activity on Monday. Stock traders bought 22,906 put options on the stock. This is an increase of approximately 450% compared to the average daily volume of 4,168 put options.

Insider Buying and Selling at Revolution Medicines

In other Revolution Medicines news, COO Margaret A. Horn sold 75,000 shares of the stock in a transaction that occurred on Wednesday, January 7th. The shares were sold at an average price of $100.56, for a total value of $7,542,000.00. Following the transaction, the chief operating officer directly owned 141,053 shares in the company, valued at approximately $14,184,289.68. This trade represents a 34.71% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Jack Anders sold 10,000 shares of Revolution Medicines stock in a transaction on Wednesday, January 7th. The stock was sold at an average price of $98.00, for a total transaction of $980,000.00. Following the transaction, the chief financial officer owned 108,065 shares in the company, valued at $10,590,370. This represents a 8.47% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 213,792 shares of company stock worth $17,948,440 over the last quarter. Company insiders own 8.20% of the company’s stock.

Institutional Trading of Revolution Medicines

Hedge funds have recently bought and sold shares of the stock. Global Retirement Partners LLC grew its position in shares of Revolution Medicines by 1,002.8% during the fourth quarter. Global Retirement Partners LLC now owns 397 shares of the company’s stock valued at $32,000 after purchasing an additional 361 shares in the last quarter. Indiana Trust & Investment Management Co bought a new position in Revolution Medicines during the fourth quarter valued at approximately $32,000. Torren Management LLC purchased a new position in Revolution Medicines during the 4th quarter valued at approximately $33,000. Darwin Wealth Management LLC bought a new stake in Revolution Medicines in the 4th quarter worth approximately $40,000. Finally, Allworth Financial LP raised its holdings in shares of Revolution Medicines by 57.2% during the 4th quarter. Allworth Financial LP now owns 577 shares of the company’s stock worth $46,000 after acquiring an additional 210 shares in the last quarter. Hedge funds and other institutional investors own 94.34% of the company’s stock.

Analysts Set New Price Targets

Several analysts have issued reports on the company. National Bankshares set a $80.00 price target on Revolution Medicines in a report on Friday, October 17th. Stifel Nicolaus initiated coverage on Revolution Medicines in a research report on Wednesday, October 15th. They set a “buy” rating and a $85.00 price objective on the stock. HC Wainwright increased their target price on shares of Revolution Medicines from $72.00 to $73.00 and gave the stock a “buy” rating in a report on Thursday, November 6th. Mizuho started coverage on shares of Revolution Medicines in a research note on Tuesday, October 21st. They set an “outperform” rating and a $90.00 target price on the stock. Finally, Royal Bank Of Canada started coverage on shares of Revolution Medicines in a report on Monday, November 3rd. They set an “outperform” rating and a $77.00 price target on the stock. Four investment analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Revolution Medicines presently has an average rating of “Buy” and an average price target of $78.94.

Revolution Medicines Price Performance

Shares of Revolution Medicines stock traded up $0.18 on Monday, hitting $97.67. 360,280 shares of the company traded hands, compared to its average volume of 4,835,675. Revolution Medicines has a 52 week low of $29.17 and a 52 week high of $124.49. The business has a 50-day simple moving average of $92.51 and a 200 day simple moving average of $64.13. The company has a debt-to-equity ratio of 0.16, a quick ratio of 8.05 and a current ratio of 8.05. The stock has a market capitalization of $18.88 billion, a P/E ratio of -18.89 and a beta of 1.01.

Revolution Medicines Company Profile

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.